WaveMan
WaveMan · Company
AORT · Artivion, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AORT Artivion (AORT) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0000784199
Quote by TradingView
Congress · 1Form 144 · 7
Insider buyers, 180 days
0
Funds added, last quarter
121
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $589.1K priced

What the filings say about AORT

Insiders, 180 days
-$3.5M net sold
4 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-08-20
Planned sales (Form 144), 90 days
$2.8M
7 notices

Artivion insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ARTIVION, INC. insiders sold a net $3.5M of stock across 250 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
GREEN ANDREW M
SVP, Regulatory and Quality
SELL
2026-09-11 SECtraded 2026-09-10
11,480
$286.7K
-8.1%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Sep 3, 2026.
  • The trade is 28.6% of the 40,160 shares held after it.
  • 3 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Regulatory and Quality GREEN ANDREW M sold about $286.7K of AORT on Sep 10, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
GREEN ANDREW M
SVP, Regulatory and Quality
SELL
2026-09-04 SECtraded 2026-09-03
1,493
$38.8K
-8.7%
Context
  • 16 earlier Form 4 trades (code P or S) here by this insider (16 sales), the last on Sep 2, 2026.
  • The trade is 2.9% of the 51,640 shares held after it.
  • 3 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Regulatory and Quality GREEN ANDREW M sold about $38.8K of AORT on Sep 3, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
GREEN ANDREW M
SVP, Regulatory and Quality
SELL
2026-09-04 SECtraded 2026-09-02
6,510
$177.5K
-8.7%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on Aug 14, 2026.
  • The trade is 12.3% of the 53,133 shares held after it.
  • 3 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Regulatory and Quality GREEN ANDREW M sold about $177.5K of AORT on Sep 2, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
Mackin James P
President & CEO
SELL
2026-08-20 SECtraded 2026-08-19
70,000
$2.0M
-18.3%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Mar 3, 2026.
  • The trade is 8.0% of the 877,275 shares held after it.
  • 3 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Mackin James P sold about $2.0M of AORT on Aug 19, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
Berry Lance A
EVP, COO, CFO & Treasurer
SELL
2026-08-17 SECtraded 2026-08-14
715
$20.4K
-20.6%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 3, 2026.
  • The trade is 0.3% of the 210,112 shares held after it.
  • 3 other insiders sold within 30 days.
  • 121 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, COO, CFO & Treasurer Berry Lance A sold about $20.4K of AORT on Aug 14, 2026; 3 other insiders sold within 30 days and 121 funds added in the latest 13F quarter.
250 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 245 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.5M over 180 days
-$2.6M over 90 days
below 72% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
121 funds bought in last quarter
more than 68% of Medical Devices
Revenue
+13.6% year over year
more than 57% of Medical Devices
Margin
2.2% net margin
more than 70% of Medical Devices
Buybacks
no share repurchases reported
Short interest
8.1% of the float short (float per yahoo 2026-10-27) · 7.2 days to cover · settled 2026-10-15
more than 79% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AORT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-47.1%12M
-54%-33%-11%+10%2025-102025-122026-022026-042026-062026-082026-10 2026-08-19 · Mackin James P sold $2.0M2025-11-13 · Mackin James P sold $1.6M2025-12-02 · Mackin James P sold $1.4M2025-12-03 · Mackin James P sold $1.4M2025-11-21 · Stanton Marshall S. sold $840.0K2026-02-23 · Mackin James P sold $788.0K2025-11-10 · Mackin James P sold $784.4K2026-03-03 · Mackin James P sold $675.8K2025-11-21 · Stanton Marshall S. sold $655.2K2026-06-11 · GREEN ANDREW M sold $620.7K2026-03-02 · Mackin James P sold $566.9K2025-11-20 · Stanton Marshall S. sold $524.7K2026-02-24 · Mackin James P sold $497.4K2025-11-11 · Holloway Jean F sold $461.8K2025-11-21 · Stanton Marshall S. sold $379.6K2026-03-04 · Holloway Jean F sold $340.6K2025-11-13 · Davis John E sold $301.0K2026-06-11 · GREEN ANDREW M sold $290.0K2025-11-17 · Holloway Jean F sold $288.8K2025-11-17 · Davis John E sold $288.8K2025-11-14 · Holloway Jean F sold $287.7K2026-09-10 · GREEN ANDREW M sold $286.7K2025-11-14 · Davis John E sold $285.6K2025-11-17 · Horton Amy sold $274.4K2025-11-13 · Holloway Jean F sold $264.2K2025-11-21 · Stanton Marshall S. sold $259.2K2026-03-03 · Berry Lance A sold $238.6K2025-12-03 · Holloway Jean F sold $238.6K2025-11-13 · Stanton Marshall S. sold $229.0K2025-12-15 · Davis John E sold $225.6K2025-12-08 · Horton Amy sold $203.1K2026-03-02 · Berry Lance A sold $196.9K2025-11-18 · Hoff Elizabeth A sold $189.4K2026-02-23 · Berry Lance A sold $187.2K2026-09-02 · GREEN ANDREW M sold $177.5K2026-03-03 · Davis John E sold $172.8K2026-02-24 · Berry Lance A sold $160.1K2025-11-13 · Horton Amy sold $159.7K2025-11-10 · Davis John E sold $150.5K2026-03-03 · Holloway Jean F sold $145.2K2026-02-23 · Davis John E sold $141.8K2025-11-10 · Holloway Jean F sold $132.1K2026-09-10 · GREEN ANDREW M filed to sell $286.7K2026-09-03 · GREEN ANDREW M filed to sell $38.8K2026-09-02 · GREEN ANDREW M filed to sell $177.5K2026-08-27 · Stanton Marshall S. filed to sell $198.7K2026-08-19 · Mackin James P filed to sell $2.1M2026-08-14 · GREEN ANDREW M filed to sell $17.6K2026-08-14 · Berry Lance A filed to sell $20.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AORT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
6,674,017 sh
$150.0M
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
3,184,974 sh
$71.6M
MORGAN STANLEY
2,557,961 sh
$57.5M
Juniper Investment Company, LLC
2,019,885 sh
$45.4M
VANGUARD CAPITAL MANAGEMENT LLC
2,004,619 sh
$45.0M

Congress trades in AORT

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Bought 2026-08-20 · disclosed 21 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-07-16 · disclosed 50 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-10-09 · disclosed 40 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AORT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
GREEN ANDREW M
Filed 2026-09-10
$286.7K
GREEN ANDREW M
Filed 2026-09-03
$38.8K
GREEN ANDREW M
Filed 2026-09-02
$177.5K
Stanton Marshall S.
Filed 2026-08-27
$198.7K
Mackin James P
Filed 2026-08-19
$2.1M

AORT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALGER WEATHERBIE SPECIALIZED GROWTH FUND
$6.9M position · as of 2026-07-31
2.9%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.7M position · as of 2026-06-30
1.8%
ROBO Global Healthcare Technology and Innovation ETF
$1.1M position · as of 2026-07-31
1.6%
Unusual Whales Subversive Democratic Trading ETF
$4.2M position · as of 2026-06-30
1.5%
AMG GW&K Small Cap Growth Fund
$2.4M position · as of 2026-07-31
1.2%
CONESTOGA SMALL CAP FUND
$21.6M position · as of 2026-06-30
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
0 active
5
Not applicable
3 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Artivion, Inc. Pac
Cycle 2026 · $10K spent
$0
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. Mackin
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.9M
$17.4M
$2.1M
+93%
+27%
2024
$5.5M
$12.3M
$1.7M
+21%
+17%
2023
$3.2M
$7.2M
$1.2M
-24%
+6%
2022
$7.2M
$4.7M
$1.8M
-49%
-3%
2021
$4.6M
$3.7M
$1.3M
-14%
+19%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.5M sold by insiders over 180 days, 121 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $2.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

AORT financials

Revenue growth
+13.6%
XBRL, annual
Net margin
2.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$471.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-0.7%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$9.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.82x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.11x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-0.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-0.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
effective tax rate 242%, not meaningful
Return on capital employed
+2.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.4B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-0.8%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$441.3M$388.5M$354.0M$313.8M
Gross profit$284.2M$248.8M$229.2M$202.5M
Operating income$33.7M$38.9M$5.7M$6.2M
Net income$9.8M-$13.4M-$30.7M-$19.2M
EPS (diluted)0.21-0.32-0.75-0.48
Operating cash flow$39.9M$22.2M$18.8M-$5.2M
Cash$64.9M$53.5M$58.9M$39.4M
Long-term debt$215.1M$314.2M$305.5M$306.5M
SEC XBRL, fiscal years, as known on 2026-10-28

AORT Stock Sonar score 6/7 axes

Find similar shapesCompare

AORT ranks highest on institutional and government (70th percentile) and profitability (68th), and lowest on insider conviction (12th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
68
Inputs
  • Return on equity-0.7% · 65 pct, sector of 183
  • Return on assets-0.3% · 68 pct, sector of 214
  • Return on invested capitaleffective tax rate 242%, not meaningful
  • Return on capital employed+2.4% · 72 pct, sector of 188
Financial health
43
Inputs
  • Debt to equity0.82x · 23 pct, sector of 159
  • Cash flow to debt0.11x · 62 pct, sector of 150
Growth
57
Inputs
  • Revenue growth, YoY+13.6% · 57 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
12
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.5M · 24 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
70
Inputs
  • Funds adding, latest quarter121 · 68 pct, sector of 191
  • Congress net buyers, 365d1 · 73 pct, universe of 718
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
37
Inputs
  • Short interest, % of float+8.1% · 30 pct, sector of 241
  • Recalls per $1B revenue, 3y6.80 per $1B · 19 pct, sector of 116
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+8.0% · 63 pct, sector of 198
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AORT filings, in plain words

Are Artivion insiders buying or selling AORT?

In the 180 days to 2026-10-28, Artivion insiders were net sellers, a net $3.5M across purchases and sales reported on Form 4, by 4 sellers.

Have members of Congress traded AORT?

Yes. In the year to 2026-10-28, 1 House member disclosed buying AORT and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-08-20.

Are there planned insider sales of AORT?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.8M of stock; the latest, by GREEN ANDREW M, was filed 2026-09-10.

Read the full summary

In the 180 days to 2026-10-28, Artivion insiders were net sellers of AORT, a net $3.5M across purchases and sales reported on Form 4 by 4 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying AORT and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-08-20. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies